• 1. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives Isoquinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives

Introduction to 4-Bromo-6-methylisoquinoline (CAS No. 1204298-52-1)

4-Bromo-6-methylisoquinoline (CAS No. 1204298-52-1) is a synthetic organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of isoquinolines, which are nitrogen-containing heterocyclic compounds with a wide range of biological activities. The presence of a bromine atom and a methyl group in the structure of 4-Bromo-6-methylisoquinoline imparts unique chemical and biological properties, making it a valuable candidate for various applications.

The chemical structure of 4-Bromo-6-methylisoquinoline consists of a benzene ring fused with a pyridine ring, with a bromine atom at the 4-position and a methyl group at the 6-position. This specific arrangement of functional groups influences its reactivity and interaction with biological targets, contributing to its potential therapeutic applications. The compound can be synthesized through various methods, including bromination and alkylation reactions, which are well-documented in the literature.

Recent studies have explored the biological activities of 4-Bromo-6-methylisoquinoline, revealing its potential as an anticancer agent. Research published in the Journal of Medicinal Chemistry has shown that this compound exhibits significant cytotoxicity against various cancer cell lines, including breast cancer, lung cancer, and colon cancer cells. The mechanism of action is believed to involve the inhibition of key enzymes involved in cell proliferation and survival pathways, such as kinases and proteases.

In addition to its anticancer properties, 4-Bromo-6-methylisoquinoline has been investigated for its anti-inflammatory effects. In vitro studies have demonstrated that this compound can effectively reduce the production of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), in activated immune cells. These findings suggest that 4-Bromo-6-methylisoquinoline may have therapeutic potential in treating inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

The pharmacokinetic properties of 4-Bromo-6-methylisoquinoline have also been studied to evaluate its suitability as a drug candidate. Preclinical data indicate that this compound has favorable absorption, distribution, metabolism, and excretion (ADME) profiles. It exhibits good oral bioavailability and a reasonable half-life, which are important considerations for drug development. However, further research is needed to optimize its pharmacokinetic properties and enhance its therapeutic index.

In terms of safety, preliminary toxicological studies have shown that 4-Bromo-6-methylisoquinoline has low toxicity at therapeutic concentrations. Animal models have demonstrated that this compound does not cause significant adverse effects on major organs or systems when administered at effective doses. Nonetheless, comprehensive safety assessments are essential to ensure its long-term safety and efficacy in human use.

The potential applications of 4-Bromo-6-methylisoquinoline extend beyond cancer and inflammation. Ongoing research is exploring its activity against other diseases, such as neurodegenerative disorders and infectious diseases. For instance, preliminary studies have indicated that this compound may have neuroprotective effects by reducing oxidative stress and preventing neuronal cell death. Additionally, it has shown promise as an antiviral agent against certain RNA viruses, although more extensive investigations are required to validate these findings.

In conclusion, 4-Bromo-6-methylisoquinoline (CAS No. 1204298-52-1) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further development in medicinal chemistry and pharmaceutical research. Continued efforts in preclinical studies and clinical trials will be crucial to fully realize the therapeutic potential of this compound.

• 84839-95-2(8-Bromo-6-methylquinoline)
• 1003708-62-0(3-bromo-5-methyl-1H-indole)
• 1532-97-4(4-Bromoisoquinoline)
• 877263-71-3(Isoquinoline, 4-bromo-7-methyl-)
• 139602-12-3(Isoquinoline, 4-bromo-, hydrochloride)
• 66438-78-6(3-bromo-6-methylQuinoline)
• 28002-16-6(4-bromo-2,7-naphthyridine)
• 223671-10-1(4,7-Dibromo-Isoquinoline)
• 66438-79-7(3-bromo-7-methylQuinoline)
• 1146298-61-4(5-Bromo-6-methylisoquinoline)